ADAR1 Capital Management LLC Boosts Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• ADAR1 Capital Management LLC increased its stake in Centessa Pharmaceuticals by 40.3%, owning approximately 0.16% of the company, valued at $3.1 million.
• Centessa Pharmaceuticals recently reported a quarterly EPS of ($0.38), missing the consensus estimate by $0.03, with analysts predicting a future EPS of -1.6.
• A majority of analysts maintain a "buy" rating on Centessa Pharmaceuticals, with target prices ranging from $30 to $40, while the average target price stands at $31.50.

ADAR1 Capital Management LLC increased its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 40.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 216,166 shares of the company's stock after buying an additional 62,139 shares during the period. ADAR1 Capital Management LLC owned 0.16% of Centessa Pharmaceuticals worth $3,108,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $31,000. Trexquant Investment LP boosted its position in Centessa Pharmaceuticals by 1.1% during the 1st quarter. Trexquant Investment LP now owns 263,994 shares of the company's stock valued at $3,796,000 after buying an additional 2,810 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after purchasing an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. bought a new position in shares of Centessa Pharmaceuticals in the 1st quarter worth about $47,000. Finally, Barclays PLC raised its holdings in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares during the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on CNTA. Wells Fargo & Company began coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday. They set an "overweight" rating and a $31.00 target price for the company. Wall Street Zen lowered shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They set a "buy" rating and a $35.00 target price for the company. Truist Financial began coverage on shares of Centessa Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $30.00 target price for the company. Finally, Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $31.45.

Centessa Pharmaceuticals Trading Down 0.4%

CNTA stock traded down $0.06 during trading on Friday, hitting $15.73. The company had a trading volume of 950,166 shares, compared to its average volume of 988,284. The firm has a market capitalization of $2.11 billion, a P/E ratio of -8.79 and a beta of 1.47. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.60 and a 52-week high of $19.09. The company has a 50 day simple moving average of $15.99 and a 200-day simple moving average of $14.46. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). As a group, research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Insider Activity

In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $17.23, for a total value of $103,380.00. Following the sale, the general counsel directly owned 105,386 shares in the company, valued at approximately $1,815,800.78. This trade represents a 5.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $15.92, for a total transaction of $875,600.00. Following the completion of the sale, the chief executive officer owned 221,017 shares of the company's stock, valued at $3,518,590.64. This trade represents a 19.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 171,322 shares of company stock valued at $2,472,814 over the last 90 days. 7.09% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.